MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
AcelRx Pharmaceuticals Total Liabilities 2011-2026 | ACRX
Annual Total Liabilities AcelRx Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.7 M | 10.2 M | 6.29 M | 25.7 M | 114 M | 122 M | 133 M | 116 M | 112 M | 105 M | 94.7 M | 39.8 M | 36.9 M | 30.7 M | 23.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 133 M | 6.29 M | 65.5 M |
Quarterly Total Liabilities AcelRx Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.6 M | 9.89 M | 9.4 M | 10.2 M | 11.4 M | 12.1 M | 12.4 M | 6.29 M | 4.95 M | 7.31 M | 12 M | 25.7 M | 20.8 M | 23 M | 110 M | 114 M | 115 M | 116 M | 115 M | 122 M | 122 M | 122 M | 122 M | 133 M | 133 M | 133 M | 133 M | 116 M | 116 M | 116 M | 116 M | 112 M | 112 M | 112 M | 112 M | 105 M | 105 M | 105 M | 105 M | 94.7 M | 94.7 M | 94.7 M | 94.7 M | 39.8 M | 39.8 M | 39.8 M | 39.8 M | 36.9 M | 36.9 M | 36.9 M | 36.9 M | 30.7 M | 30.7 M | 30.7 M | 30.7 M | 23.4 M | 23.4 M | 23.4 M | 23.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 133 M | 4.95 M | 67.8 M |
Total Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
449 M | - | - | $ 754 M |  USA |
 |
Agile Therapeutics
AGRX
|
26.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.6 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
63.2 M | - | - | $ 50.1 M | USA |
 |
Cronos Group
CRON
|
218 M | $ 2.57 | -3.02 % | $ 1.34 B |  Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
53 M | $ 4.11 | -3.95 % | $ 57.8 M | USA |
 |
Catalent
CTLT
|
6.15 B | - | - | $ 11.5 B | USA |
 |
Alimera Sciences
ALIM
|
107 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
228 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
173 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
10.3 B | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
90.4 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
250 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
367 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.56 | -2.2 % | $ 2.03 B | Canada |
 |
Organogenesis Holdings
ORGO
|
113 M | $ 2.33 | -2.92 % | $ 307 M | USA |
 |
Canopy Growth Corporation
CGC
|
430 M | $ 1.12 | -3.04 % | $ 120 M | Canada |
 |
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | USA |
 |
Pacira BioSciences
PCRX
|
775 M | $ 25.12 | -1.14 % | $ 1.16 B | USA |
 |
Harrow Health
HROW
|
347 M | $ 39.62 | -2.14 % | $ 1.46 B | USA |
 |
Lannett Company
LCI
|
735 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
9.28 M | $ 1.03 | -0.94 % | $ 1.28 M | USA |
 |
Tilray
TLRY
|
977 M | $ 6.15 | -6.25 % | $ 3.8 B | Canada |
 |
OrganiGram Holdings
OGI
|
102 M | $ 1.38 | -1.43 % | $ 402 M | Canada |
 |
Veru
VERU
|
28.1 M | $ 2.26 | -1.31 % | $ 305 M | USA |
 |
Viatris
VTRS
|
28.9 B | $ 14.99 | 1.11 % | $ 18 B | USA |
 |
Evolus
EOLS
|
249 M | $ 5.19 | -1.52 % | $ 335 M | USA |
 |
Sundial Growers
SNDL
|
235 M | $ 1.34 | -8.84 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
1.17 B | $ 8.14 | -1.03 % | $ 417 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
23.7 M | - | - | $ 193 M | Canada |
 |
Radius Health
RDUS
|
434 M | - | - | $ 1.42 B | USA |
 |
ProPhase Labs
PRPH
|
24 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
8.62 M | $ 0.82 | -11.13 % | $ 3.54 M | USA |
 |
Assertio Holdings
ASRT
|
173 M | $ 18.09 | 0.25 % | $ 116 M | USA |
 |
Solid Biosciences
SLDB
|
52.5 M | $ 7.17 | -3.83 % | $ 627 M | USA |
 |
PetIQ
PETQ
|
478 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
7.49 M | $ 7.32 | 1.1 % | $ 289 M | USA |
 |
Recro Pharma
REPH
|
94.8 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
194 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
9.65 M | $ 0.96 | -2.87 % | $ 47.9 M | USA |
 |
PLx Pharma
PLXP
|
25 M | - | -27.8 % | $ 2.56 M | USA |
 |
Aurora Cannabis
ACB
|
244 M | $ 3.32 | -3.07 % | $ 86.3 M | Canada |
 |
Zomedica Corp.
ZOM
|
11.6 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.29 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
20.2 M | $ 0.87 | -2.07 % | $ 31.3 M | USA |
 |
Tricida
TCDA
|
168 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
8.26 M | $ 0.58 | 4.11 % | $ 2.49 M |  China |
 |
TherapeuticsMD
TXMD
|
10.8 M | $ 2.09 | -0.56 % | $ 24.2 M | USA |